Eli Lilly and Co. and AstraZeneca are the latest companies to abandon Alzheimer's drug trials. The companies decided to end late-stage trials for lanabecestat, a beta secretase cleaving enzyme inhibitor, after an independent data monitoring committee determined the trials were unlikely to meet their primary goals.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.